Taiho Oncology Advances Zipalertinib in Phase 3 Trial
Princeton, New Jersey, Tokyo, Japan & Cambridge, Massachusetts, August 12, 2026 Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced...
progression-free survival
Advertisement
Enterome Reports Positive Phase 2 EO2463 Results
Paris, France | July 21, 2026 Enterome SA announced positive interim Phase 1/2 clinical data from its ongoing SIDNEY...
Kelun-Biotech Reports Phase III Success for sac-TMT in NSCLC
CHENGDU, China, July 14, 2026 Kelun-Biotech has announced a major clinical milestone after its Phase III OptiTROP-Lung06 trial evaluating...
Can-Fite Reports Positive Phase 2a Namodenoson Safety Datar
Ramat Gan, Israel, July 1, 2026 Can-Fite BioPharma Ltd. announced that its Phase 2a clinical study evaluating Namodenoson in...
Roche’s Divarasib Beats Approved KRAS Therapies in Phase III Trial
Basel, Switzerland, July 2, 2026 Roche has announced positive top-line results from its pivotal Phase III Krascendo 1 clinical...
Advertisements
Arcus Biosciences Publishes Casdatifan Kidney Cancer Data
HAYWARD, Calif., July 1, 2026 Arcus Biosciences, Inc. announced the publication of new translational research in Nature demonstrating a...
Genmab Phase 3 Epcoritamab Trial Meets Primary PFS Endpoint
COPENHAGEN, Denmark, June 29, 2026 Genmab A/S announced positive topline results from the Phase 3 EPCORE DLBCL-4 clinical trial...
Citius Oncology Reports Promising LYMPHIR Cancer Data
CRANFORD, N.J., June 1, 2026 Citius Oncology has announced encouraging Phase 1 clinical findings evaluating LYMPHIR® (denileukin diftitox-cxdl) in...
Bristol Myers Squibb Camzyos Gains FDA Priority Review
PRINCETON, N.J., June 1, 2026 Bristol Myers Squibb has achieved a significant regulatory milestone after the U.S. Food and...
Akeso’s Ivonescimab Cuts Death Risk by 34% in NSCLC
CHICAGO, Illinois, May 31, 2026 Akeso, Inc. has announced landmark results from the pivotal Phase III HARMONi-6 trial, demonstrating...
Advertisement
